Australia Bowel-Cancer Screening Program Discounted As Too Costly
This article was originally published in PharmAsia News
Australia's program for screening early for bowel cancer has come under attack for costing much more than estimated
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.